Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis

被引:34
|
作者
Ruco, LP
Stoppacciaro, A
Ballarini, F
Prat, M
Scarpino, S
机构
[1] Univ La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy
[2] Univ Piemonte Orientale A Avogadro, Dipartimento Sci Med, Novara, Italy
来源
JOURNAL OF PATHOLOGY | 2001年 / 194卷 / 01期
关键词
thyroid; papillary carcinoma; HGF; MET protein; tumour; invasiveness; dendritic cells;
D O I
10.1002/path.847
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the last 10 years, evidence has accumulated that overexpression of Met protein is a distinguishing feature of almost every case of well-differentiated papillary carcinoma. Increased expression of the protein is probably due to enhanced transcription of the MET gene and/or to post-transcriptional mechanisms. So far, alterations of the MET gene have not been recognized, but evidence has been provided that activated R.-IS and RET can cause accumulation of MET RNA. Thus, the possibility exists that dysregulation of MET is the final result of different molecular pathways capable of inducing thyroid cell transformation; RET rearrangements might account for some of the cases, but the demonstration that the majority of papillary carcinomas do not have recognized alterations of the RET gene strongly suggests that MET gene dysregulation can also be achieved through other molecular pathways. Dysregulation of MET causes marked accumulation of Met protein in tumour cells that is promptly detected by immunohistochemistry. Thus, overexpression of Met protein might represent an immunohistochemical marker of papillary carcinoma, potentially helpful in problematic cases, but caution is required; moderate expression of Met protein is observed in non-neoplastic thyroid diseases, such as Graves' and Hashimoto's thyroiditis, and reagents active on paraffin sections may have a low affinity and/or low specificity for Met protein, leading to artifactual staining. Met protein-positive papillar? carcinoma cells may produce hepatocyte growth factor (HGF) and may activate HGF through the urokinase-type plasminogen activator (uPA) bound to urokinase-type plasminogen activator receptor (uPA-R), Thus, papillary carcinoma cells possess the molecular machinery necessary for a productive HGF/ Met interaction. In vitro studies have demonstrated that HGF enhances the motility and invasiveness of tumour cells and induces the synthesis and release of chemokines active in the recruitment of dendritic cells. These observations provide a rational basis for the understanding of two distinguishing features of papillary carcinoma. First, the tumour is often characterized by early metastatic spread to regional lymph nodes and by multifocal involvement of the gland, which suggests highly invasive behaviour. Second, a prominent peritumoral inflammatory reaction is often observed, which suggests cross-talk between tumour cells and the immune system. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:4 / 8
页数:5
相关论文
共 50 条
  • [41] Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma
    Karabulut, S.
    Tas, F.
    Akyuz, F.
    Ormeci, A. C.
    Serilmez, M.
    Soydinc, H. O.
    Vatansever, S.
    Yasasever, V.
    TUMOR BIOLOGY, 2014, 35 (03) : 2327 - 2333
  • [42] Pathogenic role of hepatocyte growth factor/scatter factor (HGF) in extracapillary glomerulonephritis (EG).
    Rampino, T
    Gregorini, G
    Rastaldi, MP
    Gregorini, M
    Libetta, C
    Ranghino, A
    Soccio, G
    DalCanton, A
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A2531 - A2531
  • [43] Localization and functional role of hepatocyte growth factor (HGF) and its receptor c-met in the rat developing cerebral cortex
    Sun, W
    Funakoshi, H
    Nakamura, T
    MOLECULAR BRAIN RESEARCH, 2002, 103 (1-2): : 36 - 48
  • [44] EXPRESSION OF HEPATOCYTE GROWTH-FACTOR (HGF) AND ITS RECEPTOR C-MET IN RENAL GROWTH AND REPAIR
    HAUSMANN, MJ
    TSAO, T
    GODOWSKI, P
    SCHWALL, R
    RABKIN, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 693 - 693
  • [45] Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases
    Belfiore, A
    Gangemi, P
    Costantino, A
    Russo, G
    Santonocito, GM
    Ippolito, O
    DiRenzo, MF
    Comoglio, P
    Fiumara, A
    Vigneri, R
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (07): : 2322 - 2328
  • [46] Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma
    Tuck, AB
    Park, M
    Sterns, EE
    Boag, A
    Elliott, BE
    AMERICAN JOURNAL OF PATHOLOGY, 1996, 148 (01): : 225 - 232
  • [47] Engineering hepatocyte growth factor (HGF) as a met antagonist by impairing HGF beta-chain N-terminal insertion
    Kirchhofer, Daniel
    Lipari, Michael T.
    Santell, Lydia
    Moran, Paul
    Billeci, Karen
    Ridgway, John
    Lazarus, Robert A.
    CANCER RESEARCH, 2006, 66 (08)
  • [48] Quantitative PCR analysis of hepatocyte growth factor (HGF), its receptor (c-Met) and HGF inhibitors in breast cancer
    Parr, C
    Cunnick, GH
    Mansel, RE
    Jiang, WG
    BRITISH JOURNAL OF SURGERY, 2002, 89 : 40 - 40
  • [49] Hepatocyte growth factor (HGF) receptor expression and role of HGF during embryonic mouse testis development
    Ricci, G
    Catizone, A
    Innocenzi, A
    Galdieri, M
    DEVELOPMENTAL BIOLOGY, 1999, 216 (01) : 340 - 347
  • [50] Ontogeny of hepatocyte growth factor (HGF) and its receptor (c-met) in human placenta -: Reduced HGF expression in intrauterine growth restriction
    Somerset, DA
    Li, XF
    Afford, S
    Strain, AJ
    Ahmed, A
    Sangha, RK
    Whittle, MJ
    Kilby, MD
    AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (04): : 1139 - 1147